CONOZCA AL DR. ROBERT G. SZEWC M.D. FASN
La misión del Dr. Robert’s Szewc (Chefs) and life work are dedicated to preserving the longevity of the kidneys.
Centrarse en la atención preventiva y la educación del paciente empodera a los pacientes y sus familias para mejorar su salud y calidad de vida.
La misión y el trabajo de vida del Dr. Robert Szewc (Chefs) están dedicados a preservar la longevidad de los riñones. Centrarse en la atención preventiva y la educación del paciente empodera a los pacientes y sus familias para mejorar su salud y calidad de vida.
Además, está altamente comprometido en educar a los estudiantes de medicina y a los responsables de la toma de decisiones sobre la importancia de la salud renal y sus efectos en nuestra comunidad y sistema de atención médica.
El Dr. Szewc (Chefs) ha sido nefrólogo durante 25 años, brindando atención a mis pacientes en la comunidad de San Antonio. El objetivo de la atención que brindo es preservar, mantener e incluso revertir la insuficiencia renal. Poder ayudar a los pacientes en el difícil camino hacia el trasplante de riñón y educar a los pacientes y sus familias sobre su enfermedad a través de un enfoque holístico y convencional es más que una pasión; es algo personal para poder ayudar a cada paciente y diseñar un plan de tratamiento que se adapte a sus necesidades individuales. Me esfuerzo por preservar la longevidad de los riñones al centrarme en modificaciones en el estilo de vida y la atención preventiva como factores esenciales del plan de tratamiento completo.
Licencia Médica de Texas: L2686
Professional Training
1998 - 1999
Internal Medicine Residency
Chief Resident
UMass Memorial Healthcare
Worcester, MA
1999 - 2001
Nephrology Fellowship
UTHSCSA
San Antonio, TX
Recognition Awards
1998 - 1999
- UMass Memorial Resident Teaching Award
2003
- University Dialysis- Southeast
2010
- ESRD Fistula First Benchmark Facility Award
- ERSD Network of Texas Superior Performance in Hemodialysis
- Serum Albumin Management
- ESRD Network of Texas Hemodialysis Adequacy Management
2016
- America’s Best Physicians
2017
- Who’s Who Top Doctor
2019
- Top Doctor- Top Nephrologist
2020
- Top Nephrologist
Certificaciones
Board Certified in Internal Medicine 1999
ACLS Certification 2001
Board Certified in Nephrology 2001 and 2019
ECFMG Certificate 1993
Educación Profesional
Graduated 11/1991 M.D.- Medical School of Lublin Lublin, Poland
Licencias
Medical License in Texas (L# L2686) 2001 – 11/30/2022
Polish License to Practice Medicine - 1993
Experticia
Idiomas
See more
- Chronic Kidney Disease
- Hypertension
- Obesity and
- Chronic metabolic problem management through personalized treatment plans consisting of dietary counseling and lifestyle modification as a crucial part, along with the newest achievements of medical practice. Promoting home modalities of renal replacement therapy as a bridge to kidney transplant.
see more
- English
- Polish
- Medical Spanish
- Basic Russian
EXPERIENCIA PROFESIONAL
Cuero Lakeview Kidney Center
2004 to 2006
Cuero Lakeview Kidney Center: Cuero TX
Medical Director
Provide medical director oversight regarding clinic operation, patient safety, and patient quality outcomes at the chronic hemo-dialysis program; led the ongoing development of Standard Operating Procedures for the dialysis programs and ongoing Quality Assessment and Process Improvement activities.
Barlite Southwest Kidney Center
2004 to Present
Barlite Southwest Kidney Center: San Antonio TX
Medical Director
Provide medical director oversight regarding clinic operation, patient safety, and patient quality outcomes at the chronic hemo-dialysis program, peritoneal dialysis program and home-hemo dialysis; led the ongoing development of Standard Operating Procedures for the dialysis programs and ongoing Quality Assessment and Process Improvement activities.
San Saba Downtown Kidney Center
2004 to Present
San Saba Downtown Kidney Center: San Antonio
Medical Director
Provide medical director oversight regarding clinic operation, patient safety, and patient quality outcomes at the chronic hemo-dialysis program; led the ongoing development of Standard Operating
Procedures for the dialysis programs and ongoing Quality Assessment and Process Improvement activities.
CITAS HOSPITALARIAS
Southwest General Hospital • San Antonio, TX
July 2013
Ethics Committee Chairman
Southwest General Hospital • San Antonio, TX
June 2009 – June 2011
Health Information Management Committee
Southwest General Hospital • San Antonio, TX
June 2011 – June 2013
Pharmacy Theraputic Committee Chairman
Texas Vista Medical Center • San Antonio, TX
July 2018
Director of Acute Dialysis
RESEARCH EXPERIENCE
LIFEVEST
LIFEVEST – Wearable Cardioverter Defibrillator in Hemodialysis Patients (WED_HED) Study.
Sponsor: ZOLL, Sub-Principal Investigator: Robert G. Szewc, MD, 03/15.
ROXADUSTAT
ROXADUSTAT – A Phase 3, Multicenter, Randomized, Double–Blind, Placebo–Controlled Study Evaluating the Safety and Efficacy of XX-XXX for the Treatment of Anemia in Chronic Disease Patients not on Dialysis.
Sponsor: AstraZeneca, Principal Investigator: Robert G. Szewc, MD. 11/14
PHOSPHATE
PHOSPHATE – A Multicenter, Double – Blind Placebo – Controlled Randomized Study to Evaluate the Efficacy and Safety of XX-XXX in Subjects with Hyperphosphatemia and Dialysis – Dependent Chronic Disease.
Sponsor: Phosphate Therapeutics Ltd. (PTL) Principal Investigator: Robert G. Szewc, MD 04/14
AGMEN
AGMEN – A Randomized, Double – Blind, Placebo Controlled Study to Assess the Efficiency and Safety of Cinacalcet HCL in Chronic Kidney Disease Subjects with Secondary Hyperparathyroidism not Receiving Dialysis (Protocol 20000178.) Sub – Principal Investigator: Robert G. Szewc, MD 2005 – 2006
ABBOTT
ABBOTT – A Phase III, Randomized, Placebo-Controlled, Double-Blind, Double-Dummy, Multi-Center Study to Evaluate the Safety and Efficacy of Zemplar Capsule in reducing Serum Intact Parathyroid Levels in Chronic Kidney Disease Stage V Subjects in Hemodialysis or Peritoneal Dialysis (Protocol M03-635) Sub-Principal Investigator: Robert G. Szewc, MD 2004-2005.
AMGEN INC
AMGEN INC – A Placebo-Controlled, Double-Blinded, Multicenter Study to Assess the Efficacy and Safety of an Oral Calcimimetic Agent (AMG 073) in Secondary Hyperparathyroidism of Chronic Kidney Disease (Hemodialysis and Peritoneal Dialysis) (Protocol 20000188.) Sub-Principal Investigator: Robert G Szewc, MD 2002-2003.
NATIONAL INSTITUTE OF HEALTH
NIH – Family Investigation of Nephrology in Diabetes (FIND) 2002-2003
PATIROMER
PATIROMER – The Effect of Food: An Open – Labeled, Randomized, Parallel Group Phase 4 Study of the Efficacy and Safety of Patiromer for Oral Suspension with or without food for the treatment of Hyperkalemia (TOURMALINE.) Sub- Principal Investigator: Robert G. Szewc, MD, 03/15
NABI PHARMACEUTICALS, INC – A Phase III, Multicenter, Randomized, Placebo- Controlled, Double – Blinded Study to Evaluate Efficacy of Staph V AX, a Blvalent Staphylococcus Eureus Glycocanjugate Vaccine In Adults on Hemodialysis (Protocol 1371) Sub-principal Investigator: Robert G Szewc, MD 2004-2005
AMGEN INC – A Placebo-Controlled, Double-Blinded, Multicenter Study to Assess the Efficacy and Safety of an Oral Calcimimetic Agent (AMG 073) in Secondary Hyperparathyroidism of Chronic Kidney Disease (Hemodialysis and Peritoneal Dialysis) (Protocol 20000188.) Sub-Principal Investigator: Robert G Szewc, MD 2002-2003.
ABBOTT LABORATORIES INC. – A Phase III, Prospective, Randomized, Placebo-Controlled, Double-Blind, Multicenter, Study to Evaluate the Safety and Efficacy of Zemplar Capsule (Dosed Three Times Weekly) in reducing Elevated Serum Intact Parathyroid Hormone Levels in Subject with Chronic Kidney Disease (Protocol 2001020). Principal Investigator: Robert G. Szewc MD 2002-2003
NIH – Family Investigation of Nephrology in Diabetes (FIND) 2002-2003
ABBOT LABORATORIES INC. – A Phase III, Prospective, Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Safety of Xemplar Capsules in Reducing Serum Intact Parathyroid Hormone Levels in End Stage Renal Disease Subjects on Hemodialysis (Protocol 2001-013)
Principal Investigator: Robert G Szewc 2002-2003
KERYX
KERYX – A Phase 3 Study of XX-XXX for the treatment of Iron Deficiency Anemia in Adult Subject with Non-Dialysis Dependent Chronic Kidney Disease.
Sponsor: Keryx Biopharmaceuticals, Principal Investigator: Robert G. Szewc 09/14
SHIRE
SHIRE – A Phase IV, Open- Label, Multi- Center Trial Evaluation the Efficacy of Fosrenal (Lanthum Carbonate) Compared to Existing Therapy in Adults with End Stage Renal Disease Treated for Hyperphosphatemia, (Protocol SPD 405 – 401) Principal Investigator: Robert G. Szewc, MD 2005 – 2006
ABBOTT LABORATORIES, INC
ABBOTT LABORATORIES, INC – A Phase IV, Prospective, Randomized, Active – Controlled, Double- Blind, Double – Dummy, Multi – Center study to Evaluate the Survival Benefits of Zemplar Relative to Calcilex in Subjects with Stave V Chronic Kidney Disease on Hemodialysis. (Protocol M02 – 516) Sub – Principal
Investigator: Robert G. Szewc, MD. 2003 – 2004
NABI PHARMACEUTICALS, INC
NABI PHARMACEUTICALS, INC – A Phase III, Multicenter, Randomized, Placebo- Controlled, Double – Blinded Study to Evaluate Efficacy of Staph V AX, a Blvalent Staphylococcus Eureus Glycocanjugate Vaccine In Adults on Hemodialysis (Protocol 1371) Sub-principal Investigator: Robert G Szewc, MD 2004-2005
ABBOTT LABORATORIES INC
ABBOTT LABORATORIES INC. – A Phase III, Prospective, Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Zemplar Capsule (Dosed Three Times Weekly) in reducing Elevated Serum Intact Parathyroid Hormone Levels in Subject with Chronic Kidney Disease (Protocol 2001020). Principal Investigator: Robert G. Szewc MD 2002-2003
ABBOT LABORATORIES INC
ABBOT LABORATORIES INC. – A Phase III, Prospective, Randomized, Placebo-Controlled, Double- Blind, Multicenter, Study to Evaluate the Safety of Xemplar Capsules in Reducing Serum Intact Parathyroid Hormone Levels in End Stage Renal Disease Subjects on Hemodialysis (Protocol 2001-013)
Principal Investigator: Robert G Szewc 2002-2003
PUBLICACIONES
Tratamiento de la Enfermedad de las Arterias Coronarias Sintomáticas en Pacientes con Enfermedad Renal en Etapa Terminal en Hemodiálisis con Stent TAXUS con Liberación de Paclitaxel
Treatment of Symptomatic Coronary Artery Disease in Patients with End-Stage Renal Disease on Hemodialysis with Paclitaxel-eluting TAXUS Stent. Szymon L Wiernek, R. Stefan Jiesz, Barbara K. Wiernek, Portr P. Buzman, Adam Janas, Jack L. Martin, Blazej Trela, Robert G. Szewc, Pawel E Buszman. Hemodialysis International 2015;19:402-411.
Extracción de Placa Debajo de la Rodilla para Salvamento de Extremidad en Pacientes con Enfermedad Renal en Etapa Terminal y Diabetes
Plaque Excision Below the Knee for Limb Salvage in Patients with End Stage Renal Disease and Diabetes. R.S. Kiesz, P. Buszman, M.A. Walker, R.G.Szewc, M.W. McQueen, San Antonio Endovascular and Heart Institue; Silesian Medical School, Katowice, Poland; Catheterization and Cardiovascular Interventions. 2006 May; 67 (5): 755. Also to be published in European Heart Journal 2006.
Colocación de Stents Renales con Registro Prospectivo de Protección contra la Embolización Distal; Experiencia Preliminar
Renal Stenting with Distal Embolization Protection Prospective Registry; Preliminary Experience, R.S. Kiesx, R. Szewc, T. Ybarra, M. Walker. San Antonio Endovascular and Heart Institute, San Antonio, Texas, Catheterization and Cardiovascular Interventions. 2005 May; 65(1): 152.
Predicción del TFG en Candidatos a Trasplante de Hígado
Prediction of GFR in Liver Transplant Candidates. Skluzacek PA, R.G. Szwec, Nolan CR 3rd Riley DJ, Lee S, Pergola PE. Department of Medicine, Wilford Ha; Medical Center, Lackland Air Force Base, San Antonio, Texas; Am J Kidney Dis. 2003 Dec. 42(6); 1169-76